[HTML][HTML] Treatment of liver fibrosis: Past, current, and future

CY Zhang, S Liu, M Yang - World Journal of Hepatology, 2023 - ncbi.nlm.nih.gov
Liver fibrosis accompanies the progression of chronic liver diseases independent of
etiologies, such as hepatitis viral infection, alcohol consumption, and metabolic-associated …

Flavonoids from Whole-Grain Oat Alleviated High-Fat Diet-Induced Hyperlipidemia via Regulating Bile Acid Metabolism and Gut Microbiota in Mice

R Duan, X Guan, K Huang, Y Zhang, S Li… - Journal of Agricultural …, 2021 - ACS Publications
A high-fat diet (HFD) causes hyperlipidemia, which worsens disturbances in bile acid (BA)
metabolism and gut microbiota. This study aimed to investigate the regulation of flavonoids …

Bile acid sequestrants for hypercholesterolemia treatment using sustainable biopolymers: Recent advances and future perspectives

MS Islam, A Sharif, N Kwan, KC Tam - Molecular pharmaceutics, 2022 - ACS Publications
Bile acids, the endogenous steroid nucleus containing signaling molecules, are responsible
for the regulation of multiple metabolic processes, including lipoprotein and glucose …

Bile acids as metabolic regulators: an update

T Li, JYL Chiang - Current Opinion in Gastroenterology, 2023 - journals.lww.com
Basic and clinical studies have continued to discover novel roles of the enterohepatic bile
acid signaling in regulation of key metabolic pathways. Such knowledge forms the molecular …

New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease

Y Liu, T Liu, X Zhao, Y Gao - Cellular and Molecular Life Sciences, 2022 - Springer
Cholestasis is a key causative factor in alcohol-related liver disease (ALD) and variable
degrees of cholestasis occur in all stages of ALD. However, the pathogenetic mechanisms …

[HTML][HTML] Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice

RF Kunst, I Bolt, RDJ van Dasselaar, BA Nijmeijer… - JHEP Reports, 2024 - Elsevier
Background & Aims Intestine-restricted inhibitors of the apical sodium-dependent bile acid
transporter (ASBT, or ileal bile acid transporter) are approved as treatment for several …

[HTML][HTML] Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases

SG Rodrigues, S van der Merwe, A Krag… - Seminars in immunology, 2024 - Elsevier
“A healthy liver stands on a healthy gut” with the gut and its barriers representing the roots
that fuel the liver and expose it to an amazing diverse mixture of gut-derived material/agents …

Ilexsaponin A1 Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism in Mice

W Zhao, M Xiao, X Wu, X Li, X Li, T Zhao… - Frontiers in …, 2021 - frontiersin.org
Bile acid (BA) metabolism is an attractive therapeutic target in nonalcoholic fatty liver
disease (NAFLD). We aimed to investigate the effect of ilexsaponin A1 (IsA), a major …

Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice

MN Hasan, J Chen, D Matye, H Wang, W Luo… - Journal of Lipid …, 2023 - ASBMB
Therapeutic reduction of hydrophobic bile acids exposure is considered beneficial in
cholestasis. The Cyp2c70 KO mice lack hydrophilic muricholic acids and have a human-like …

Bile acid signaling in metabolic and inflammatory diseases and drug development

T Li, JYL Chiang - Pharmacological Reviews, 2024 - pharmrev.aspetjournals.org
Bile acids are the end products of cholesterol catabolism. Hepatic bile acid synthesis
accounts for a major fraction of daily cholesterol turnover in humans. Biliary secretion of bile …